Back to rankings

Mettler-Toledo International Inc (MTD)

Overvalued
HealthcareDiagnostics & ResearchSwitzerland

Fundamental

62

Price

$1670.29

Market Cap

$33.62B

Part 1 · What the company is worth

Overview

Mettler-Toledo is a global leader in precision weighing and analytical instruments serving pharmaceutical, biotech, food manufacturing, chemical, academic, and retail sectors. The company operates the world's largest installed base of weighing instruments and maintains market-leading positions across laboratory analytics, industrial process scales, and retail point-of-sale systems. With operations in approximately 40 countries and products sold in over 140 countries, the company employs approximately 9,000 field personnel in sales and service roles, positioning itself as a comprehensive solutions provider rather than a pure equipment manufacturer.

How it makes money

The company generates revenue through four primary streams: equipment sales of laboratory instruments, industrial scales, and analytical systems (approximately 76% of revenue); service contracts including calibration, maintenance, regulatory compliance support, and remote services (24% of revenue as of 2024, up from 20% in 2022); software platforms connecting instruments to customer IT systems (LabX, FreeWeigh.Net, and proprietary control software); and replacement parts and consumables including pipette tips and reagents. Service revenue is strategically expanding and carries higher margins, serving as a customer retention tool and providing recurring cash flow.

Revenue by segment

Laboratory Instruments56%

Precision analytical instruments including laboratory balances, process analytics equipment, and automated chemistry solutions sold to pharmaceutical, biotech, research, and academic institutions. This segment includes the LabX software platform and serves customers with the highest regulatory compliance requirements (FDA, GMP, GLP standards).

Industrial Instruments39%

Industrial weighing systems, product inspection equipment, and process control instruments serving food manufacturers, chemical companies, transportation/logistics, metals, and electronics sectors. Products include networked scales, in-motion weighing systems, X-ray and metal detection systems, and related software for production optimization and quality control.

Retail Weighing Solutions5%

Point-of-sale weighing systems and associated software for food retail establishments. Products facilitate accurate pricing and traceability of fresh foods including produce, meat, and seafood in supermarkets and specialty retailers.

Competitive moat

Scale · Wide

Mettler-Toledo possesses a durable, wide moat rooted in multiple sources: the world's largest installed base of weighing instruments creates substantial customer switching costs and installed-base leverage for service penetration. The company holds global market-leading positions in most of its segments, reinforced by approximately 5,400 patents and trademarks. Its sales and service network—among the largest in precision instruments with 9,000 field personnel across 40 countries—creates distance that regional competitors cannot easily close. Service revenue (24% of total, growing from 20% in 2022) generates recurring cash flow with high margins. Deep regulatory expertise in FDA, GMP, and GLP compliance serves pharmaceutical and biotech customers for whom switching carries operational risk. The company's scale enables investments in R&D (5% of sales annually, $189 million in 2024) that smaller competitors cannot match, maintaining innovation leadership across laboratory and industrial segments.

What drives demand

Moderately cyclical

Demand exhibits moderate cyclicality with both defensive and cyclical characteristics. The business benefits from defensive elements: pharmaceutical, biotech, and life sciences research are growing secular trends that support underlying demand for analytical instruments; regulatory compliance requirements (FDA, GMP, GLP standards) mandate purchasing even during downturns. Food safety regulations and supply chain digitalization trends provide ongoing demand drivers. However, the business carries significant cyclical exposure: customers 'often decrease or delay capital expenditures' during economic uncertainty or recession. Laboratory and industrial equipment purchases are discretionary capital investments sensitive to customer profitability and credit availability. Demand is volatile in emerging markets where economic conditions change rapidly. Seasonality patterns show Q4 historically generating 27-30% of annual sales, with Q1 slightly lower, reflecting project cycles and budget spending patterns.

Key risks

  • China Market Concentration and Declining Demand — China represents 16% of 2024 net sales and 29% of global segment profit, yet market demand declined significantly in the second half of 2023 and continued declining through 2024, particularly in core segments including pharma/biopharmaceutical and food manufacturing. Geopolitical tensions between the United States and China create additional uncertainty around tariffs, trade restrictions, and supply chain disruptions.
  • Economic Cyclicality and Customer Capital Expenditure Delays — Customer demand is highly sensitive to economic cycles. Customers 'often decrease or delay capital expenditures' during economic downturns, recessions, or periods of macroeconomic uncertainty. Manufacturing lead times are short (typically one to two months) and the company carries minimal backlog, limiting revenue visibility and the ability to buffer against demand shocks. Seasonality patterns—with Q4 historically generating 27% to 30% of annual sales—amplify cyclical effects as fixed costs distribute unevenly across quarters.
  • Cybersecurity Threats and Data Breach Risks — The company faces 'ransomware, falsification of banking and other information, insider risk' and other cybersecurity threats. State-sponsored cyber attacks are increasing in sophistication. Despite mitigation measures, 'our systems remain potentially vulnerable.' Data breaches affecting customer critical information could damage customer relationships and trigger regulatory compliance costs (GDPR, etc.). The filing does not provide specific incident history but identifies cybersecurity as an elevated operational risk.
  • Geopolitical Tensions, Tariffs, and Supply Chain Disruptions — The Ukraine invasion and Middle East conflicts create supply chain disruptions, energy cost increases, and shipping capacity constraints. U.S.-China trade tensions introduce tariff uncertainty and risk of export control or economic sanctions restrictions on fund repatriation. The company acknowledges 'geopolitical tensions have increased, particularly between the United States and China,' impacting operations and profitability.
  • Competitive Pressures from Regional and Low-Cost Competitors — The company faces 'competitive pressures from regional specialists and emerging market competitors with lower cost structures.' Customers may purchase lower-cost competitor products during economic downturns. While Mettler-Toledo holds market-leading positions, sustained R&D investment and sales support are required to maintain competitive advantage, creating ongoing capital intensity.
  • Supply Chain and Single-Supplier Dependencies — The company faces 'single-supplier dependency for certain components' and general raw material availability and cost pressures. Manufacturing capacity constraints and global supply chain volatility create operational risk. Production dependencies in China (representing 30% of global production) compound geopolitical exposure.

Customer concentration

The company maintains a highly diversified customer base with zero material concentration risk: 'no single end-customer accounts for more than 1% of 2024 net sales.' Customers span multiple industries including pharmaceutical and biotech (life sciences), food manufacturing and retail, chemical and specialty chemicals, academic research institutions, electronics and metals industries, and transportation/logistics. This diversification across geographies and end-markets significantly reduces revenue vulnerability from individual customer loss.

The case for

Buyers argue that Mettler-Toledo's global market leadership in precision weighing and analytical instruments creates a durable, wide-moat business with significant barriers to entry through the world's largest installed base and 5,400+ patents. The company's shift toward recurring service revenue (now 24% of sales, up from 20% in 2022) with higher margins provides more stable, predictable cash flow and customer retention. The pharmaceutical and biotech sectors driving 56% of revenue (laboratory segment) benefit from secular growth in life sciences research, healthcare spending, and regulatory compliance requirements that mandate Mettler-Toledo's products for FDA/GMP/GLP certification. With no customer concentration (no customer >1% of sales), the business is resilient to individual customer loss. The Blue Ocean program streamlining operations to a single-instance ERP system should drive margin expansion. Geographic diversification (42% Americas, 28% Europe, 30% Asia) limits dependence on any single region, while R&D investment of 5% of sales annually supports continued innovation leadership.

The case against

Sellers fear that significant China market exposure (16% of sales, 29% of segment profit) represents a deteriorating growth driver amid prolonged demand decline in China's pharmaceutical, biopharmaceutical, and food manufacturing sectors since late 2023. Geopolitical tensions, U.S.-China tariff risks, and production dependencies (30% of global production in China) create compounding operational and tariff uncertainty. The business exhibits structural cyclicality: customers decrease or delay capital expenditures during economic downturns, making revenue highly sensitive to macroeconomic conditions. With only one to two months of manufacturing backlog and short lead times, the company has minimal revenue visibility and limited ability to buffer against demand shocks. Economic uncertainty in developed markets threatens customer capital spending plans. Competitive pressures from regional specialists and emerging market low-cost competitors threaten margins. Seasonality (Q4 historically 27-30% of annual sales) creates lumpy revenue and fixed-cost challenges. Cybersecurity threats and data breach risks could damage customer relationships. While the installed base provides leverage for service revenue, the company faces execution risk in achieving service penetration targets amid competitive saturation.

Generated with artificial intelligence on September 21, 2026, shared with all users

Direct competitors

Who this company fights with for the same customers

Compare

Generated with artificial intelligence on September 19, 2026, shared with all users

P/E: 36.2Score: 72Market cap: $256.61B

Thermo Fisher supplies the same laboratory customers with overlapping lines of analytical instruments, pipettes and process analytics, and competes for the large multi-year supply contracts of pharmaceutical and biotech labs.

P/E: 34.1Score: 76Market cap: $50.11B

Agilent competes for the same analytical-chemistry budget in pharmaceutical and industrial quality-control labs, with chromatography, spectroscopy and lab software that substitute for Mettler-Toledo's analytical instruments.

P/E: 113.1Score: 64Market cap: $44.95B

Waters sells chromatography, mass spectrometry and thermal-analysis systems to the same regulated pharmaceutical and materials laboratories where Mettler-Toledo places its thermal analysis and titration instruments.

P/E: 37.7Score: 73Market cap: $164.53B

Through its life-sciences and diagnostics brands Danaher bids for the same laboratory and bioprocessing equipment, consumables and service contracts, often bundling them across global accounts.

Sartorius AGNot tracked

Sartorius is the closest head-to-head rival in laboratory weighing, selling analytical and precision balances, pipettes and lab consumables to the same pharmaceutical, chemical and academic laboratories.

Shimadzu Corporation (島津製作所)Not tracked

Shimadzu builds balances, moisture analyzers and analytical instruments for the same industrial and laboratory customers, and is the main rival for Mettler-Toledo in Japan and much of Asia.

Balance Sheet & Liquidity

Revenue

$4.13B

Trailing 12 months (through 6/30/2026)

Net Income

$906M

Trailing 12 months (through 6/30/2026)

Free Cash Flow

$849M

Total Equity

$-24M

Total Liabilities

$3.74B

Current Ratio

1.12

Interest Coverage

-

Debt/EBITDA

1.66

Earnings Per Share

Revenue & Net Income

Free Cash Flow

Income Breakdown

Historical statement

Margins over time

Debt over time

How heavy the debt is

Growth grid

Growth — Revenue

Fair Value Estimation

General caseOvervalued

Fair Value

$1239.81

Current Price

$1670.29

Margin of Safety

-34.7%

Fair Value Range

$835.93 - $1643.70

Spread across the valuation methods used, not a statistically calibrated confidence interval.

Estimation Methods

Analyst price target:$1529.46
Discounted cash flow (DCF):$812.16
Earnings multiple (P/E):$1579.01
Graham growth formula:$1198.86
Earnings power value (EPV):$387.52
Justified P/B:$236.81
Dividend discount (Gordon):Not enough data to compute it
P/FFO, funds from operations:Not enough data to compute it
Mid-cycle earnings:Not enough data to compute it
Revenue multiple:$774.57
Last Earnings Surprise:+5.18%

Valuation Metrics

P/E Ratio

37.65

ROE

-3677.4%

P/B Ratio

2609.91

P/FCF

38.74

Gross Margin

60.3%

ROIC

-

Profitability Radar

Value Creation (Economic Moat)

ROIC

-

WACC

10.6%

ROIC − WACC

-

Fundamental Analysis Criteria

Passed (16)

  • EPS shows upward trend
  • EPS CAGR 12.37%
  • Price CAGR 14.42%
  • Gross margin 60.3%
  • Positive free cash flow
  • CapEx intensity
  • Current ratio
  • Debt/EBITDA
  • Return on tangible assets
  • ROE 1,816.3%
  • Revenue growth 5Y 5.5%
  • Earnings surprise, average 3.4%
  • Earnings quality (operating cash flow / net income) 1.08
  • Share dilution -3.1%
  • Net margin trend 21.9% vs 21.5%
  • Piotroski F-Score 6/9

Failed (6)

  • P/FCF 38.74
  • P/B ratio 2,609.91
  • Low reliance on intangibles
  • Price below Graham Number
  • DCF valuation (Overvalued)
  • PEG ratio 3.33

Unavailable (5)

  • ROIC –
  • Dividend payout –
  • Debt/equity ratio
  • Operating margin –
  • Interest coverage

Piotroski F-Score

6/9

Mixed signals: some areas need attention

ROA > 0
Operating cash flow > 0
ΔROA > 0
Cash flow > net income
Leverage ↓
Current ratio ↑
No dilution
Gross margin ↑
Asset turnover ↑

Earnings Quality

1.08

High quality: earnings backed by cash

Share Dilution

-3.1%

Buying back shares. Shareholder friendly

Institutional Holdings

Governance

Executive Team

NameTitleAge
Mr. Patrick K. KaltenbachPresident & CEO62
Mr. Shawn P. VadalaChief Financial Officer56
Ms. Susan Graham-BryceChief Human Resources Officer49
Mr. Marc de La GueronniereHead of North American Market Organization, Global Service & Commercial Excellence61
Mr. Richard WongHead of Asia/Pacific60
Mr. Markus KoepfliChief Information Officer-
Mr. Adam William UhlmanHead of Investor Relations-
Ms. Michelle M. RoeChief Legal Officer & Corporate Secretary54
Mr. Oliver WittorfHead of Product Inspection, Retail & Global Supply Chain49
Mr. Gerhard KellerHead of Process Analytics57

Audit Risk

2

Board Risk

1

Compensation Risk

6

Shareholder Rights Risk

5

Documents

  • Annual Report (10-K)

    A yearly overview of the business, its financial results, and the risks it faces.

    Filed on 2026-02-06

    View document
  • Quarterly Report (10-Q)

    A snapshot of financial performance for the most recent three-month period.

    Filed on 2026-07-31

    View document
  • Current Report (8-K)

    An announcement of a major event, such as a leadership change or big news.

    Filed on 2026-08-03

    View document

via SEC EDGAR

Income History

via SEC EDGAR

Part 2 · The price and its context

This part shows how the price has behaved, not whether the company is worth owning. Inside: technical analysis, potential, historical drawdowns, gamma exposure.

Market Reaction Profile

How much MTD moves, measured on its daily prices.

VolatilityLow

More volatile than 25% of the tracked stocks (90-day volatility).

Volatility 30d
27.0%
Volatility 90d
26.5%
Beta vs S&P 500 (1y)
0.79Correlation 0.32
Max drawdown (12m)
-31.9%
ATR (14d, % of price)
2.49%

Earnings reactions

How MTD moved around its past quarterly results.

Next earnings release

Nov 5, 2026 · In 12 days · Time not known

EPS estimate: 12.09Revenue estimate: $1.1B

What usually happens

  • Over the last 12 releases the stock moved a median of 3.5% the next day, up or down.
  • Next-day moves: up 4, down 8 (out of 12).
  • Of the 4 releases that beat estimates, the stock fell the next day after 3.

Release history

DateWhen EPS est.EPS actualSurprise Gap 1 day5 days
Jul 30, 2026After the close10.9011.46+5.2% +6.1% +2.6% +2.9%
May 7, 2026After the close8.798.91+1.4% -9.6% -14.8% -21.0%
Feb 5, 2026After the close12.9313.36+3.3% +0.1% -0.7% -1.8%
Nov 6, 2025After the close10.7411.15+3.8% -1.3% 0.0% -1.9%
Jul 31, 2025After the closen/an/an/a0.0% -3.0% +0.3%
May 1, 2025After the closen/an/an/a+1.7% +4.1% +4.3%
Nov 7, 2024After the closen/an/an/a-4.9% -7.2% -12.3%
Aug 1, 2024After the closen/an/an/a-3.4% -4.9% -7.9%
May 9, 2024After the closen/an/an/a+7.7% +17.0% +18.6%
Feb 8, 2024After the closen/an/an/a+1.3% -4.1% -2.6%
Nov 9, 2023After the closen/an/an/a-2.0% +1.9% +2.5%
Jul 27, 2023After the closen/an/an/a-4.8% -1.2% -4.2%

Release dates from SEC 8-K filings.

Updated 10/24/2026

Historical statistics for educational purposes only. They are not forecasts and not investment advice.

Price reaction to the news

Latest news on MTD and what the price did next.

No positive or negative news on MTD has been archived yet.

Return of the stock minus return of SPY over the same days. A news item close to a price move did not necessarily cause it. Historical data for educational purposes only, not investment advice.

Latest News

Recent headlines for MTD.

No recent news for MTD.